Skip to content
Government Federal, Medical Health Aged Care

PHAA thanks Professor Paul Kelly, outgoing Chief Medical Officer, for his commitment to public health

Public Health Association of Australia < 1 mins read

8 October 2024

The Public Health Association of Australia (PHAA) acknowledges the contribution of Professor Paul Kelly as he announces his departure from the role of Chief Medical Officer of Australia (CMO) and Director of the Interim Centre for Disease Control.

Professor Kelly commenced as Deputy CMO in January 2020 as COVID-19 was emerging. He became acting CMO in July 2020 and was appointed CMO in January 2021.

“A public health physician and infectious disease epidemiologist, Professor Kelly was the right man to offer leadership to Australia during the COVID-19 pandemic,” said PHAA CEO, Adjunct Professor Terry Slevin.

“Few people will appreciate the extraordinary pressures and challenges of being the Chief Medical Officer during a global health emergency. Professor Kelly played a vital role in helping Australia navigate through that crisis.

“All people in Australia owe Professor Kelly a debt of gratitude for his dedication and leadership during a perilous time in history.

“We also thank Professor Kelly for his commitment to the development of the Australian Centre for Disease Control.

“We wish Professor Kelly all the best in his future endeavours.”


About us:

About the Public Health Association of Australia

We’re Australia's peak body for public health and advocate for the health and wellbeing of everyone. We strive to help prevent, rather than cure, illness and disease.

Our campaigns and activities span numerous public health issues from environmental health, immunisation and pandemic control, through to tobacco, gambling, physical activity, junk food marketing, preventive mental health, health education and Aboriginal and Torres Strait Islander health.

Our 2,000+ individual members represent over 40 professional groups interested in the promotion of public health. We also have branches in every State and Territory. Learn more at phaa.net.au


Contact details:

Jasmine Lykissas, PHAA Communications Officer, 0481159618, jlykissas@phaa.net.au  

Media

More from this category

  • Disability, Medical Health Aged Care
  • 20/12/2024
  • 17:36
Kuremara

Kuremara to Open a State-of-the-Art Activity Center in Milton, QLD, in January 2025

Kuremara, a trusted and leading NDIS-registered provider in Australia, is excited to announce the opening of its newest facility—a cutting-edge activity center in Milton,…

  • Contains:
  • Legal, Medical Health Aged Care
  • 20/12/2024
  • 17:29
JGA Saddler

BREAKING NEWS: Australian law firm takes on Johnson & Johnson for selling Australians ineffective medicine

Vision available: Lawyer and doctor VNR, editorial photos and radio grabs included can be found in this SharePoint File In-person lawyer interviews available by…

  • Contains:
  • Medical Health Aged Care
  • 20/12/2024
  • 12:01
NDARC/UNSW

ADHD drug shows promise for treating methamphetamine dependence, landmark Australian study shows

A prescription medication used to treat attention deficit hyperactivity disorder (ADHD) could be repurposed as the first pharmacotherapy for people with methamphetamine dependence, according to a study published in Addiction. Results from the landmark ‘LiMA’ trial show that thepsychostimulant lisdexamfetamine can drastically reduce the need to use methamphetamine among those who are dependent on the illicit drug. Lead author and addiction medicine specialist Professor Nadine Ezard, who is Director of the National Centre for Clinical Research on Emerging Drugs (NCCRED), said the results were promising. "There is currently no pharmacotherapy approved for treating methamphetamine dependence," Professor Ezard said. “While further…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.